كتاب
ADVANCED/METASTATIC BREAST CANCER
- Research Gaps
• Head-to-Head comparison for adjuvant Olaparib versus Capecitabine in TNBC received neoadjuvant treatment with residual disease.
• Pembrolizumab neoadjuvant exclusively versus neoadjuvant and adjuvant regarding survival benefit, toxicity including financial toxicity and quality of life.
• This guideline will be updated whenever there is new evidence.
• Randomized trials to determine the risks and benefits of brain screening in TNBC needed.
